Trial Profile

A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 15 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DJI 136 (Primary)
Indications Neuroendocrine carcinoma; Small cell lung cancer
Focus Adverse reactions; First in man

Most Recent Events

22 May 2026 Preliminary results from Phase 1 data for LB2102 presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, according to the Legend Biotech Corporation Media Release.
22 May 2026 Results presented in the Legend Biotech Corporation Media Release.
24 Mar 2026 Planned End Date changed from 1 Mar 2028 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com